[{"id":"a5c7185c-9670-454c-8ccc-75c5b9dce3b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05684965","created_at":"2023-01-13T14:59:18.253Z","updated_at":"2024-07-02T16:35:15.101Z","phase":"Phase 1","brief_title":"XTX301 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05684965","lead_sponsor":"Xilio Development, Inc.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e efarindodekin alfa (XTX301)"],"overall_status":"Recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 05/11/2023","start_date":" 05/11/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-03-12"}]